This proposal contains specific features of the studies on the oncogenicity of Marek's disease virus (MDV).
In specific aims I, II and III, we plan to study the detailed aspect of D-H region which is uniquely expanded in nonpathogenic strains of MDV and which may contain a possible tumor inducing gene of MDV. We will obtain more biological evidence that D-H region may be needed for tumor induction and/or transformation. This will be done by proposed studies such as co-transfection of nonpathogenic viral DNA with D-H fragment to recover pathogenic viral strain, transformation or immortalization of cells by D-H transfection, and determination of tumorgenicity in chicken for viruses with normal D-H and expanded D-H, plaque purified from a weakly oncogenic virus strain. MDV-induced lymphoblastic cell DNA will be tested for NIH 3T3 cell transformation to examine whether chicken cell DNA sequence may be present for inducing HIH 3T3 cell transformation. Structure and transcriptional patterns of D-H region will be studied. D-H gene products will be synthesized by mammalian vector or bacterial plasmid and characterized. Other unique structural features of MDV DNA will also be studied. Other viral genes actively transcribed in transformed cells and tumors will be identified. Finally, DNA of herpesvirus turkey (HVT), which is used as a vaccine for prevention of MD, will be physically mapped by restriction enzymes and colinearity of viral DNA between MDV and HVT will be determined. Cross-reactive antigens between MDV and HVT will be assigned to the maps of both virus by in vitro transplantation method. This study will be important for the future genetic study of MDV and HVT.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA031949-06
Application #
3170047
Study Section
Experimental Virology Study Section (EVR)
Project Start
1981-08-01
Project End
1988-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
6
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Tampa Bay Research Institute
Department
Type
DUNS #
City
Saint Petersburg
State
FL
Country
United States
Zip Code
33716
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900
Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25
Davidson, I; Tanaka, A; Nonoyama, M (1995) Common antigenic epitopes are present on heat-labile oligomers of MDV glycoprotein B and on HSV glycoprotein B. Virus Res 35:233-45
Peng, Q; Zeng, M; Bhuiyan, Z A et al. (1995) Isolation and characterization of Marek's disease virus (MDV) cDNAs mapping to the BamHI-I2, BamHI-Q2, and BamHI-L fragments of the MDV genome from lymphoblastoid cells transformed and persistently infected with MDV. Virology 213:590-9
Makimura, K; Peng, F Y; Tsuji, M et al. (1994) Mapping of Marek's disease virus genome: identification of junction sequences between unique and inverted repeat regions. Virus Genes 8:15-24
Peng, F; Bradley, G; Tanaka, A et al. (1992) Isolation and characterization of cDNAs from BamHI-H gene family RNAs associated with the tumorigenicity of Marek's disease virus. J Virol 66:7389-96
Nonoyama, M; Wen, L T; Tanaka, A et al. (1990) Detection of 12-o-tetradecanoylphorbol-13-acetate-induced cellular proteins that compete with the Epstein-Barr virus nuclear antigen 1 (EBNA-1) for binding to a site within the Epstein-Barr virus oriP. Adv Exp Med Biol 278:125-36
Wen, L T; Lai, P K; Bradley, G et al. (1990) Interaction of Epstein-Barr viral (EBV) origin of replication (oriP) with EBNA-1 and cellular anti-EBNA-1 proteins. Virology 178:293-6

Showing the most recent 10 out of 21 publications